Altres autors/es

Institut Català de la Salut

[Søreide K] Department of Gastrointestinal Surgery, HPB Unit, Stavanger University Hospital, Stavanger, Norway. Department of Clinical Medicine, University of Bergen, Bergen, Norway. Division of Surgery and Oncology, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden. [Dopazo C] Servei de Cirurgia Hepatobiliopancreàtica i Trasplantaments, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Berrevoet F] Department of General and HPB Surgery and Liver Transplantation, Ghent University Hospital, Ghent, Belgium. [Carrion-Alvarez L] Department of General Surgery, HPB Unit, Fuenlabrada University Hospital, Madrid, Spain. [Diaz-Nieto R] Hepatobiliary Surgery Unit, Liverpool University Hospital, Liverpool, UK. [Andersson B] Department of Clinical Sciences Lund, Surgery, Lund University and Skåne University Hospital, Lund, Sweden

Vall d'Hebron Barcelona Hospital Campus

Data de publicació

2025-05-30T06:36:06Z

2025-05-30T06:36:06Z

2024

2025-06



Resum

Bile duct cancer; Chemotherapy; Cholangiocarinoma


Càncer de les conducte biliar; Quimioteràpia; Colangiocarinoma


Cáncer de las vías biliares; Quimioterapia; Colangiocarcinoma


Background Biliary tract cancers comprise a heterogeneous collection of malignancies usually described as cholangiocarcinoma of the intra- or extrahepatic bile duct, including perihilar cholangiocarcinoma and gallbladder cancer. Methods A review of pertinent parts of the ESSO core curriculum for the UEMS diploma targets (Fellowships exam, EBSQ), based on updated and available guidelines for diagnosis, surgical treatment and oncological management of cholangiocarcinoma. Results Following the outline from the ESSO core curriculum we present the epidemiology and risk factors for cholangiocarcinoma, as well as the rationale for the current diagnosis, staging, (neo-)adjuvant treatment, surgical management, and short- and long-term outcomes. The available guidelines and consensus reports (i.e. NCCN, BGS and ESMO guidelines) are referred to. Recognition of biliary tract cancers as separate entities of the intrahepatic biliary ducts, the perihilar and distal bile duct as well as the gallbladder is important for proper management, as they each provide distinct clinical, molecular and treatment profiles to consider. Conclusion Core competencies in knowledge to the diagnosis, management and outcomes of biliary tract cancers are presented.

Tipus de document

Article


Versió publicada

Llengua

Anglès

Publicat per

Elsevier

Documents relacionats

European Journal of Surgical Oncology;51(6)

https://doi.org/10.1016/j.ejso.2024.108489

Citació recomanada

Aquesta citació s'ha generat automàticament.

Drets

Attribution 4.0 International

http://creativecommons.org/licenses/by/4.0/

Aquest element apareix en la col·lecció o col·leccions següent(s)